Miniatura

Fitxers

653578.pdf (6.64 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-07-13

Llicència de publicació

cc-by (c) Ruiz de Garibay, G. et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/69339

Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1371/journal.pone.0132546

Resum

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-ß3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.

Matèries

Càncer de mama, Metàstasi, Marcadors tumorals, Càncer de pulmó

Matèries (anglès)

Breast cancer, Metastasis, Tumor markers, Lung cancer

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

RUIZ DE GARIBAY, Gorka, HERRANZ, Carmen, LLORENTE, Alicia, BONI, Jacopo, SERRA-MUSACH, Jordi, MATEO GONZÁLEZ, Francesca, AGUILAR, Helena, GÓMEZ BALDÓ, Laia, PETIT, Anna, VIDAL-BEL, August, CLIMENT, Fina, HERNÁNDEZ-LOSA, Javier, CORDERO, Alex, GONZÁLEZ SUÁREZ, Eva, SANCHEZ-MUT, Jose vicente, ESTELLER, Manel, LLATJÓS, Roger, VARELA RODRÍGUEZ, Mar, LÓPEZ, José ignacio, GARCÍA, Nadia, EXTREMERA, Ana i., GUMÀ I GARCIA, Anna maria, ORTEGA, Raúl, PLA FARNÓS, María jesús, FERNÁNDEZ, Adela, PERNAS, Sònia, FALO ZAMORA, Catalina, MORILLA, Idoia, CAMPOS, Miriam, GIL, Miguel, ROMÁN, Antonio, MOLINA MOLINA, María, USSETTI, María piedad, LAPORTA, Rosalía, VALENZUELA, Claudio, ANCOCHEA BERMÚDEZ, Julio, XAUBET MIR, Antonio, CASANOVA, Álvaro, PUJANA GENESTAR, M. ángel. Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness. _PLoS One_. 2015. Vol. 10, núm. 7, pàgs. e0132546. [consulta: 24 de gener de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/69339]

Exportar metadades

JSON - METS

Compartir registre